Altimmune's weight-loss drug meets main goal in fatty liver disease trial
26/06/2025 12:25
June 26 (Reuters) - Altimmune ALT.O said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. (Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave